Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Its Second Biotech Deal In Three Months, Ranbaxy Signs Pact With Pfenex For An Undisclosed Biosimilar

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Moving one step closer to realizing its ambitions in the fast-emerging biosimilars space, Daiichi Sankyo's Indian arm Ranbaxy signed a development deal with the San Diego-based Pfenex, a spin-off of the Dow Chemical Company

You may also be interested in...

Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics

MUMBAI - Lucrative opportunities in the business of vaccines has attracted one more big drug maker. India's Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008

Indian Tribunal Back Zenotech, Daiichi Sankyo's Struggle On Open Offer Price Continues

MUMBAI - Daiichi Sankyo's year-long struggle to wrest control of India's biotech and oncology start-up Zenotech Labs received yet another setback as the Securities Appellate Tribunal backed the founder promoters of the Hyderabad-based company led by Jayaram Chigurupati and asked the Japanese company to increase the offer price for the shares to further bolster its shareholding

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts